Brussels - Delayed Quote EUR

Fagron NV (FAGR.BR)

16.70

+0.08

+(0.48%)

At close: 5:35:13 PM GMT+1

Fagron acquires Brazilian plastic packaging producer Injeplast

The move forms part of a larger expansion as Fagron has also acquired CareFirst Specialty Pharmacy.

Packaging Gateway 7 days ago

FAGR.BR
+0.48%
Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil Fagron, the leading global player in pharmaceutical compounding is pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron’s commitment to expanding across our key markets whils

GlobeNewswire 7 days ago

ARSUF
Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufactu

GlobeNewswire 22 days ago

ARSUF
Disclosure of notification received from FMR LLC

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC. Notification by FMR LLC On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the

GlobeNewswire last month

ARSUF
Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12.2% organic growth at C

GlobeNewswire 3 months ago

ARSUF
Fagron SA (ARSUF) Q2 2024 Earnings Call Highlights: Strong Growth and Upgraded Revenue Guidance

Fagron SA (ARSUF) reports robust revenue growth and improved margins, with significant gains in North America and an optimistic outlook for the full year.

GuruFocus.com 3 months ago

FAGR.BR
+0.48%
Disclosure of notification received from AOC Pharma S.à r.l.

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from AOC Pharma S.à r.l. Notification by AOC Pharma S.à r.l. On 3 October 2024, Fagron received a notification that changes took place in the chain of controlled undertakings through which the share

GlobeNewswire 3 months ago

ARSUF
Fagron completes share buy-back program

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period from 9 September 2024 through 13 September 2024, Fagron purchased 45,000 of its owns shares at an average price of € 19.10 per share corresponding to a total amount of € 859,324.10. A total of 150,000 Fagron shares have been repurchased under the buy-back program at an averag

GlobeNewswire 3 months ago

ARSUF
Fagron’s share buy-back program: Weekly update

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2024, Fagron purchased 33,500 of its owns shares at an average price of € 19.17 per share corresponding to a total amount of € 642,302.02. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which

GlobeNewswire 4 months ago

ARSUF
Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates (CER)) and 12.8% o

GlobeNewswire 5 months ago

ARSUF
Fagron shareholders approve all voting items at AGM and EGM

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders and extraordinary general meeting of shareholders today. Both meetings approved all. voting items. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30

GlobeNewswire 7 months ago

ARSUF
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the

GlobeNewswire 8 months ago

ARSUF
Record revenue of €209 million in first quarter reflecting 15% topline growth

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regionsOrganic growth at CER of 12.3%

GlobeNewswire 8 months ago

ARSUF
Disclosure notification from Mawer Investment Management Ltd.

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Mawer Investment Management Ltd. that its shareholding crossed the 5% disclosure threshold as the result of the acquisition of voting securities or voting rights on 15 March 2024. N

GlobeNewswire 9 months ago

ARSUF
Fagron publishes annual report 2023

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English translatio

GlobeNewswire 9 months ago

ARSUF
Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 February 2024 – 7AM CET Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its full year results for the period ending 31 December 2023. Key Highlights Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5% organic revenue growth at CER supported

GlobeNewswire 10 months ago

ARSUF

Performance Overview

Return	FAGR.BR	BEL 20
YTD	-0.24%	-0.60%
1-Year	-1.80%	+14.02%
3-Year	+12.01%	-1.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fagron NV (FAGR.BR)

Fagron acquires Brazilian plastic packaging producer Injeplast

Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

Disclosure of notification received from FMR LLC

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Fagron SA (ARSUF) Q2 2024 Earnings Call Highlights: Strong Growth and Upgraded Revenue Guidance

Disclosure of notification received from AOC Pharma S.à r.l.

Fagron completes share buy-back program

Fagron’s share buy-back program: Weekly update

Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024

Fagron shareholders approve all voting items at AGM and EGM

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Record revenue of €209 million in first quarter reflecting 15% topline growth

Disclosure notification from Mawer Investment Management Ltd.

Fagron publishes annual report 2023

Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

Performance Overview